• Owens & Minor, Inc. (NYSE: OMI) announced that its President and CEO, Ed Pesicka, and CFO, Jon Leon, will participate in a fireside chat at 1:25 p.m.
• Eastern Daylight Time on Tuesday, September 10, 2024.
• The chat will take place at Baird’s Global Healthcare Conference in New York City.
RICHMOND, Va. / Sep 09, 2024 / Business Wire / Owens & Minor, Inc. (NYSE: OMI), announced today that Ed Pesicka, the Company’s President and Chief Executive Officer and Jon Leon, Corporate Treasurer and interim Chief Financial Officer, will participate in a fireside chat at 1:25 p.m. Eastern Daylight Time on Tuesday, September 10, 2024 at Baird’s Global Healthcare Conference in New York City. Owens & Minor is also hosting one-on-one meetings with investors at the conference.
About Owens & Minor
Owens & Minor, Inc. (NYSE: OMI) is a Fortune 500 global healthcare solutions company providing essential products and services that support care from the hospital to the home. For over 100 years, Owens & Minor and its affiliated brands, Apria®, Byram® and HALYARD*, have helped to make each day better for the patients, providers, and communities we serve. Powered by more than 20,000 teammates worldwide, Owens & Minor delivers comfort and confidence behind the scenes so healthcare stays at the forefront. Owens & Minor exists because every day, everywhere, Life Takes Care™. For more information about Owens & Minor and our affiliated brands, visit owens-minor.com or follow us on LinkedIn and Instagram.
| Last Trade: | US$15.81 |
| Daily Change: | -0.06 -0.38 |
| Daily Volume: | 741,676 |
| Market Cap: | US$1.220B |
September 10, 2024 August 02, 2024 July 23, 2024 July 23, 2024 May 28, 2024 | |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
